enGene TherapeuticsENGN
Recorded

enGene Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

David DaiBiotech Analyst

I think we're ready to go. Great. Thanks, everyone. Thanks everyone for joining. This is our fireside chat with enGene. My name is David Dai. I'm a biotech analyst here at UBS. I cover mostly oncology, and it's a great pleasure to have Ron Cooper, Chief Executive Officer of enGene with us today.

Ron CooperCEO

Ron, welcome. David, real pleasure to be here.

Ron CooperCEO

Thank you for the invitation.

David DaiBiotech Analyst

Fantastic. enGene, very interesting story. Maybe, Ron, can just from a high-level perspective, just to help us understand a little more about enGene's story, especially you have a very interesting lead program called detalimogene. Tell us more about that.

Ron CooperCEO

Yeah. enGene is a unique company in that our company is focused on non-viral gene therapies. We have a unique platform called the DDX platform. From that platform, we have a product called detalimogene voraplasmid, which we're developing for non-muscle invasive bladder cancer. What's exciting about detalimogene is it's a well-advanced asset. We just put out some data very recently. We'll talk about that in a little bit. This is an asset that we plan to file the BLA by the end of this year, and we're going to expect an approval next year. What's pretty exciting is that we translated this unique technology, this non-viral gene therapy, into a medicine that we hope to have in the hands of urologists and patients with non-muscle invasive bladder cancer very soon.

David DaiBiotech Analyst

Got it. Yeah, very interesting. So a non-viral approach towards HR NMIBC, non-muscle invasive bladder cancer. You know, the space is a little bit crowded, especially given the fact that there is adenovirus and others. Tell us a little bit more about this mechanism of this non-viral approach, and how is it different from the other approach that we are looking at here?

Ron CooperCEO

Well, it is totally unique, right? I think that is what makes it very, very special, because as you have indicated, David, there are chemo approaches, there are viral gene therapy approaches, and there are bacterial approaches. We are the only non-viral gene therapy. What makes detalimogene unique is it is actually a simple plasmid, not an LNP, with three genes in it, with our proprietary sugar that is pegylated. What is beautiful about that is that these are all readily available ingredients, and they are relatively easy to put together, so we have a very competitive cost of goods. Because it is non-viral, the handling, there is an aspect of cost of goods is handling, shipping, storage. This is a non-viral, so it is a lot easier to ship, handle, and store.

Ron CooperCEO

What is interesting about our approach is that combination of genes that we use, two RIG-I and one IL-12, that stimulates both the innate and adaptive immune system. So, when people are thinking about managing non-muscle invasive bladder cancer, which we believe is going to be a disease that gets sequenced much like multiple myeloma or others, detalimogene will be unique. It will be a different product within that sequence.

David DaiBiotech Analyst

Hmm. Got it. Just on that administration side, you said this is pretty convenient. Tell us a little bit more about, is this similar to BCG where you are doing transvesical delivery, and the handling, would you expect physician to use it kind of similar to what they are doing with BCG already?

Ron CooperCEO

BCG and better. So, yeah, it is intravesical. All these therapies are intravesical or administered. But, it's interesting, we recently had a patient in at the office talking about BCG therapy. We kind of take it for granted. But BCG therapy is an hour and a half dwell time. It's six weeks. It's intense. It has cumulative toxicity with it. The urine bleaching requirements require people two cups of bleach, right? So when you think about your lifestyle and things, if you're going to restaurants or if you're going to concerts or traveling, you're going to lug around all that bleach. When you think about detalimogene, first of all, is stored in a regular fridge or regular freezer, so same place where you put your ice cream or where you put your yogurt.

Ron CooperCEO

Yeah. No special handling. Someone just reaches into the fridge, mixes with water.

Ron CooperCEO

There's no pre-washes or anything like instill, and the patient can go from there. And then you see from our recent data that the tolerability profile is really quite impressive. We have the lowest treatment discontinuation rate and treatment interruption rate. So that's really a measure of the tolerability. So in fact, I would argue it's even easier than BCG to use.

David DaiBiotech Analyst

Got it. So better administration, easier to use BCG, and off the shelf, I would imagine, you know, you just grab it from the fridge and administer it. So, very good. And the data, I think you just showed some interesting data last week, right? So help us walk us through that dataset. What did we learn from that?

Ron CooperCEO

Well, we learned that detalimogene is highly efficacious and well-tolerated on top of the great handling. So if we break it down for the efficacy parameters, all of our efficacy parameters improved since our last update, which is great. So when you think about it from an FDA perspective, the primary endpoint is complete response at any time. The detalimogene CR rate moved from 54% to 56%, which puts it right in the middle of the range of approved products. The next thing the FDA looks at is safety and tolerability, as I indicated to you. Even with increased exposures, the profile still holds really strong and with a very low rate of discontinuations, very low rate of treatment interruptions, really the lowest of all the products.

Ron CooperCEO

From a secondary endpoint perspective, the secondary endpoint is of those 56% of patients, what percentage are still in response 12 months and beyond? Most of the products, the approved products are in the 40s or 50s. Our Kaplan-Meier curve estimates that that will be 43%, and that jumped up from 25% to 43%. The other measures of durability that are looked at is median duration of response. Again, ours moved from 8.6 to 10.1, and when you look at the confidence interval, the upper limit has not been reached yet, so there is still some time to get more. The last parameter, which is somewhat of a durability measure, although it is not in the label and it is not promotable, is the 12-month landmark complete response rate.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day